Advertisement

Organisation › Details
Sanofi (Group) [since May 2011]
Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *
![]() |
Start | 2011-05-06 renamed |
Predecessor | Sanofi-Aventis (Group) | |
![]() |
Industry | pharmaceutical |
![]() |
Person | Hudson, Paul (Sanofi 201909– CEO before Novartis Head Pharma before AstraZeneca + Schering-Plough) |
Person 2 | Contamine, Jérôme (Sanofi 2009–201809 CFO RETIRED 9/18) | |
![]() |
Region | Paris |
Country | France | |
Street | 174 avenue de France | |
City | 75635 Paris | |
Tel | +33-1-5377-4000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | I: 50,001 to 100,0 (2020-12-31) |
Currency | EUR | |
Annual sales | 36,041,000,000 (sales, net, consolidated (2020) 2020-12-31) | |
Profit | 12,350,000,000 (2020-12-31) | |
Cash | 13,915,000,000 (2020-12-31) | |
* Document for �About Section�: | ||
Record changed: 2021-04-12 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Sanofi (Group) [since May 2011]
- [1] Sanofi S.A.. (4/9/21). "Press Release: Sanofi Acquires Tidal Therapeutics, Adding Innovative mRNA-based Research Platform with Applications in Oncology, Immunology, and other Disease Areas". Paris & Cambridge, MA....
- [2] Enterome S.A.. (3/10/21). "Press Release: Enterome Strengthens Its Leadership Team with the Appointment of Anne Dagallier as Chief Business Officer"....
- [3] Hyloris Pharmaceuticals S.A.. (2/3/21). "Press Release: Hyloris Appoints Marieke Vermeersch as VP of Investor Relations and Corporate Communications". Liège....
- [4] Biond Biologics Ltd.. (1/12/21). "Press Release: Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor". Misgav....
- [5] Sanofi S.A.. (1/11/21). "Press Release: Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L". Paris & Cambridge....
- [6] Jeito Capital. (11/13/20). "Press Release: Sanofi Selects Jeito Capital as Its First Investment into a Private French-based Fund". Paris....
- [7] Kiadis Pharma N.V.. (11/2/20). "Press Release: Sanofi Offers to Acquire Kiadis for €308 Million". Paris & Amsterdam....
- [8] Sanofi S.A.. (8/17/20). "Press Release: Sanofi to Acquire Principia Biopharma". Paris & South San Francisco, CA....
- [9] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK in Advanced Discussions with European Union to Supply up to 300 Million Doses of COVID-19 Vaccine". London & Paris....
- [10] GlaxoSmithKline plc. (7/31/20). "Press Release: Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 vaccine". London & Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top